###begin article-title 0
Expression of small breast epithelial mucin (SBEM) protein in tissue microarrays (TMAs) of primary invasive breast cancers
###end article-title 0
###begin p 1
Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.
###end p 1
###begin title 2
Aims
###end title 2
###begin p 3
###xml 209 210 209 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
Small breast epithelial mucin (SBEM) is a recently described gene product that shows promise as a new breast biomarker. The aim was to investigate for the first time SBEM protein expression in a large cohort (n = 300) of invasive breast cancers, its relationship to established clinical variables and its association with clinical outcome.
###end p 3
###begin title 4
Methods and results
###end title 4
###begin p 5
###xml 183 184 175 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 286 287 278 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 358 359 350 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 454 455 444 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 561 562 551 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 716 717 706 707 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 730 731 720 721 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Immunohistochemical analysis was performed on tissue microarrays consisting of 149 oestrogen receptor (ER) alpha- and 151 ERalpha+ breast cancers. Overall, 18% of tumours were SBEM+ (n = 53/300). However, SBEM protein was more frequently observed in ER- (22%) than in ER+ cancers (13%; P = 0.049). A significant association with psoriasin/S100A7 expression (P</= 0.0001) was observed in the entire cohort. SBEM was also positively associated with HER-2 (P = 0.046) in ER- cancers, and increased levels of SBEM were strongly associated with higher tumour grade (P = 0.0015). Furthermore, SBEM expression showed a trend towards an association with reduced overall survival and relapse-free survival in the ER+ cohort (P = 0.063 and P = 0.072, respectively).
###end p 5
###begin title 6
Conclusions
###end title 6
###begin p 7
Our results suggest that SBEM may identify a unique subset of breast cancers with poor prognosis and may have future implications for therapeutic management of this disease.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 132 133 132 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1">1</xref>
###xml 134 135 134 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2">2</xref>
###xml 228 229 228 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2">2</xref>
###xml 315 316 315 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3">3</xref>
###xml 317 318 317 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4">4</xref>
###xml 46 51 <span type="species:ncbi:9606">women</span>
###xml 103 108 <span type="species:ncbi:9606">women</span>
###xml 186 191 <span type="species:ncbi:9606">women</span>
###xml 397 404 <span type="species:ncbi:9606">patient</span>
Breast cancer is the most common cancer among women and is the second leading cause of cancer death in women in developed countries.1,2 The 5-year survival rate is approximately 75% for women with locally advanced breast cancer.2 However, if the cancer has metastasized, the average survival time falls to <2 years,3,4 and at such time a very limited number of treatment options are available for patient management.
###end p 9
###begin p 10
###xml 200 201 200 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5">5</xref>
###xml 202 203 202 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7">7</xref>
###xml 222 223 222 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-</italic>
###xml 418 419 418 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b8">8</xref>
###xml 499 503 499 503 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MUC1</italic>
###xml 692 693 692 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9">9</xref>
###xml 694 696 694 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b15">15</xref>
###xml 1434 1436 1434 1436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16">16</xref>
###xml 1437 1439 1437 1439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b18">18</xref>
###xml 637 642 <span type="species:ncbi:9606">human</span>
###xml 809 816 <span type="species:ncbi:9606">patient</span>
###xml 908 915 <span type="species:ncbi:9606">patient</span>
To date, oestrogen receptor (ER) and progesterone receptor (PR) are the two most useful clinical markers predicting response to hormonal therapy in both metastatic disease and in the adjuvant setting.5-7 More recently, HER-2, which is overexpressed in 25% of breast cancers and is associated with aggressive disease and poor prognosis, has also been used in the clinical setting, as a prognostic and predictive marker.8 Many other markers have been or are being investigated, including the mucin 1 (MUC1) gene product and related tumour antigens (CA27.29), carcinogenic embryonic antigen, cathepsin D, gross cystic disease fluid protein/human prolactin inducible protein, mammaglobin and p53.9-15 Because breast cancer encompasses a highly heterogeneous group of tumours, our failure to treat or cure a given patient may result from our inability to match the particular phenotype of the tumour cells of the patient with the appropriate treatment. Therefore, there is an urgent need to identify and evaluate new breast biomarkers for monitoring both progression and treatment of the disease. Prognostically significant clusters of breast cancers have recently been identified by a number of investigators reporting on gene profiling and tissue microarray (TMA) analyses. The biologically distinct groups of markers defining these tumour clusters are likely to have real clinical and prognostic/diagnostic relevance in the near future.16-18 Identification of tumour markers with expression that is restricted to the mammary epithelium would have a significant impact not only on reporting proliferative changes in the breast (which may predict increased risk of breast cancer development), but also on enhancing the detection of micrometastatic disease by identifying cancer cells of breast origin in lymph nodes.
###end p 10
###begin p 11
###xml 35 39 35 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SBEM</italic>
###xml 142 144 142 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19">19</xref>
###xml 145 147 145 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b22">22</xref>
###xml 147 151 147 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SBEM</italic>
###xml 360 362 360 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">20</xref>
###xml 399 403 399 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SBEM</italic>
###xml 549 551 549 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19">19</xref>
###xml 552 554 552 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">20</xref>
###xml 722 726 722 726 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SBEM</italic>
###xml 829 831 829 831 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19">19</xref>
###xml 832 834 832 834 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">20</xref>
###xml 848 852 848 852 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SBEM</italic>
###xml 959 961 959 961 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19">19</xref>
###xml 962 964 962 964 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">20</xref>
###xml 1274 1276 1274 1276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b23">23</xref>
The small breast epithelial mucin (SBEM) gene, also known as BS106 and/or B511S, was originally identified as a putative breast-specific gene.19-22SBEM encodes a secreted 90 amino acids glycoprotein, which consists of a secretion signal peptide, three tandemly repeated octapeptide motifs (TTAAXTTA) and exhibits characteristics of members of the mucin family.20 Dot blot analysis has revealed that SBEM RNA is highly expressed in normal breast and salivary glands, but not in other normal tissues tested, including prostate, lung, ovary and testis.19,20 Similarly, reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of cDNA extracted from various cancer cell lines has revealed consistently high levels of SBEM in breast cancer cell lines (7/8), whereas none of the six non-mammary cell lines tested was positive.19,20 Furthermore, SBEM gene expression, as assessed by RT-PCR, has been observed in >90% of primary or metastatic breast cancers.19,20 Moreover, it has recently been demonstrated that the combined use of SBEM, cytokeratin (CK) 19, trefoil factor-3 (p1B) and epithelial glycoprotein-2 (EGP-2) expression allows the identification of micrometastases in sentinel node biopsy specimens of breast cancers, missed by standard histological evaluation.23
###end p 11
###begin p 12
###xml 159 161 159 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19">19</xref>
###xml 270 274 270 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SBEM</italic>
###xml 878 886 <span type="species:ncbi:9606">patients</span>
Overall, the accumulated data so far suggest that the utility of SBEM as a new breast cancer marker may be promising. However, with the exception of one study,19 which was carried out on a very small cohort of breast cancers, all studies conducted to date have examined SBEM mRNA expression. In the latter study an increase of SBEM protein expression in tumours versus normal breast tissue was observed. To date, there have been no reports in which large cohorts of selected breast cancer cases have been evaluated for SBEM protein expression and in which differences in SBEM protein expression by subject characteristics have been examined. In the present study, we have investigated SBEM protein expression by immunohistochemistry (IHC) in TMAs and its association with other established markers of prognosis, in a large cohort of invasive breast cancers corresponding to 300 patients.
###end p 12
###begin title 13
Materials and methods
###end title 13
###begin title 14
Breast tumour tissue microarrays
###end title 14
###begin p 15
###xml 269 271 269 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b24">24</xref>
###xml 1537 1540 <span type="species:ncbi:9685">cat</span>
All invasive breast cancers used in the current study were obtained from the Manitoba Breast Tumour Bank (MBTB, Department of Pathology, University of Manitoba), which operates with the approval of the Faculty of Medicine, University of Manitoba, Research Ethics Board.24 As described previously, all tissues are accrued to the bank from cases at multiple centres within Manitoba, which are collected and frozen at -70degreesC immediately after surgical removal. A portion of the frozen tissue from each case is then processed to create matched formalin-fixed paraffin-embedded and frozen tissue blocks. The histopathology of all MBTB cases has been previously assessed and entered into a computerized database to enable selection based on composition of the tissue as well as clinicopathological parameters. After selection, cases were re-reviewed on haematoxylin and eosin sections by a breast pathologist (P.H.W.). ER+ and ER- TMAs were constructed from cohorts of 246 ERalpha+ and 255 ERalpha- primary invasive ductal breast carcinomas, respectively. In brief, duplicate core tissue samples (0.6 mm diameter) were taken from selected areas of maximum cellularity for each tumour with a tissue arrayer instrument (Beecher Instruments, Silver Spring, MD, USA). Only tumour biopsy specimens whose ER status was determined both by ligand binding assay (LBA; ER+ >3 fmol/mg protein) and by IHC were included. Ultimately, 300 cases provided reliable information. In addition, a commercially available TMA (Biomax Inc., Rockville, MD, USA; cat. No. BN08013, ) consisting of 68 normal breast tissue biopsy specimens was also analysed by IHC.
###end p 15
###begin title 16
###xml 39 46 <span type="species:ncbi:9606">patient</span>
Clinicopathological characteristics of patient cohorts
###end title 16
###begin p 17
###xml 88 90 88 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b25">25</xref>
###xml 879 880 873 874 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 958 959 952 953 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 995 996 989 990 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1044 1045 1038 1039 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1081 1082 1075 1076 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1109 1110 1103 1104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1149 1150 1143 1144 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1178 1179 1172 1173 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1202 1203 1196 1197 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1284 1285 1278 1279 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1362 1363 1356 1357 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1399 1400 1393 1394 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1435 1436 1429 1430 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1466 1467 1460 1461 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1513 1514 1507 1508 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 195 202 <span type="species:ncbi:9606">patient</span>
###xml 889 897 <span type="species:ncbi:9606">patients</span>
###xml 1224 1232 <span type="species:ncbi:9606">patients</span>
###xml 1294 1302 <span type="species:ncbi:9606">patients</span>
###xml 1486 1493 <span type="species:ncbi:9606">patient</span>
The recommendations for tumour marker prognostic studies (REMARK) as reported by McShane25 were followed as closely as possible. Case selection was based on the following criteria: (i) a minimum patient follow-up of 60 months; (ii) tumours had an invasive component of >20% of the tissue section, and </=10% of the normal epithelial content; (iii) ER- status was defined by LBA criteria of </=3 fmol/mg protein. The criteria for interpretation of the variables were as follows: (i) PR+ status was defined as >10 fmol/mg protein by LBA; (ii) tumour grading was consistent with the Nottingham system (scores 3-5 = low; 6-7 = moderate; and 8-9 = high); (iii) tumour size was classified as either small (</=20 mm) or large (>20 mm); (iv) tumour inflammation was assessed on a scale from 1 to 5 and then assigned to low (score 1-3) or high (score 4 and 5) categories. In the ER- TMA (n = 149), patients received a variety of treatments, such as hormonal therapy (n = 21), hormonal plus radiotherapy (n = 6), hormonal, radiotherapy and chemotherapy (n = 13), hormonal plus chemotherapy (n = 4), radiotherapy alone (n = 5), radiotherapy plus chemotherapy (n = 43), chemotherapy alone (n = 32), surgery alone (n = 21), and for four patients the treatment regimen was unknown. In the ER+ TMA (n = 151), patients received the following treatments: hormonal therapy alone (n = 92), hormonal plus radiotherapy (n = 56), hormonal and chemotherapy (n = 1) and radiotherapy alone (n = 1), whereas one patient had surgery alone (n = 1).
###end p 17
###begin title 18
Breast cancer sections
###end title 18
###begin p 19
###xml 507 515 <span type="species:ncbi:9606">patients</span>
Ten pairs of matched frozen and paraffin-embedded breast cancers were selected from the MBTB for examining SBEM gene and protein expression. Serial tissue sections obtained from these biopsy specimens were evaluated for gene expression by both RT-PCR and Northern blot analysis, whereas protein expression was assessed by IHC and Western blot analysis. ER and PR levels ranged from 2.3 to 180 fmol/mg protein and 4.5 to 105 fmol/mg protein, respectively (nine ER+ and eight PR+ breast cancers). The ages of patients were between 58 and 78 years, and tumour size varied from 15 to 50 mm.
###end p 19
###begin title 20
RNA and protein extraction
###end title 20
###begin p 21
###xml 275 277 270 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b26">26</xref>
###xml 361 362 356 357 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 366 367 361 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</italic>
###xml 419 420 414 415 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 446 447 438 439 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 492 493 481 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</italic>
###xml 494 495 483 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</italic>
###xml 496 497 485 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</italic>
###xml 499 500 488 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</italic>
###xml 531 532 520 521 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 553 554 542 543 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 881 882 870 871 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
###xml 881 882 870 871 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>g</italic></bold>
###xml 1003 1005 980 982 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b27">27</xref>
Total RNA was extracted from 20-mum frozen tissue sections (10-20 sections/tumour) using the Trizol(R) RNA extraction protocol (Trizol(R); Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Protein extraction was carried out as previously described.26 Briefly, tissues were homogenized in ice-cold homogenization buffer containing 20 mm 3-(N-morpholino)-propanesulfonic acid (pH 7.2-7.5), 60 mmbeta-glycerophosphate, 5 mm ethylene glycol-bis (beta-aminoethyl ether)-N,N,N',N'-tetraaceticacid (pH 8.0), 5 mm sodium fluorate, 1 mm sodium vanadate, 1% NP40 (all from Sigma, St Louis, MO, USA) and a mini-protease inhibitor cocktail tablet (Boehringer Mannheim, Indianapolis, IN, USA) per 10-ml extraction buffer and sonicated several times using an ultrasonic cell disrupter (Sonics & Materials, Inc., Danbury, CT, USA). Sonicates were centrifuged at 13 000 g for 20 min at 4degreesC and stored at -20degreesC until use. Protein concentration was determined using the Lowry assay.27
###end p 21
###begin title 22
RT-PCR analysis
###end title 22
###begin p 23
###xml 98 100 92 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12">12</xref>
###xml 216 220 210 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SBEM</italic>
###xml 270 274 264 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SBEM</italic>
###xml 339 343 333 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SBEM</italic>
###xml 454 455 448 449 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 479 480 473 474 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 491 492 485 486 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 497 498 491 492 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 506 507 499 500 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 677 682 669 674 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 714 717 706 709 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAP</italic>
###xml 769 772 761 764 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAP</italic>
###xml 1203 1207 1177 1181 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SBEM</italic>
###xml 1271 1275 1245 1249 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SBEM</italic>
###xml 1409 1414 1383 1388 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 1430 1437 1404 1411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl2">Table 2</xref>
###xml 1444 1448 1418 1422 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SBEM</italic>
###xml 1537 1541 1511 1515 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SBEM</italic>
###xml 1559 1566 1533 1540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl2">Table 2</xref>
###xml 168 174 <span type="species:ncbi:10090">murine</span>
Two micrograms of total RNA was reverse-transcribed for 1 h at 37degreesC as previously described.12 A negative control for the RT-PCR was included in which no Moloney murine leukaemia virus (MMLV) enzyme was added. SBEM primers consisted of a forward primer designated SBEM-U (5'-gatcttcaggtcaccaccatg-3') and a reverse primer designated SBEM-L (5'-gggacacactctaccattcg-3'). Two microlitres of each reverse transcription mixture, in the presence of 20 mm Tris-HCl (pH 8.4), 50 mm KCl, 1.5 mm MgCl2, 200 mum of each dNTP, 200 ng of each primer and 0.5 U of Taq DNA polymerase, was used for PCR in a final volume of 50 mul. Primers for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) consisted of a forward primer GAP-U (5'-acccactcctccacctttg-3') and a reverse primer GAP-L (5'-ctcttgtgctcttgctggg-3'). PCR products were visualized with UV irradiation on a GelDoc2000/ChemiDoc System (BioRad, Hercules, CA, USA) and quantified by densitometry using QuantityOne software (version 4.2; BioRad). Three independent PCRs (35 cycles; 15 s at 94degreesC, 15 s at 52degreesC and 15 s at 72degreesC) were performed from each separate RT reaction and the average of the relative signals was calculated. Briefly, SBEM signals in breast tumour no. 4 were arbitrarily set as 1.0 and SBEM signals in all other samples were quantified relative to tumour no. 4. This strategy was also employed for the quantification of the GAPDH (control gene, Table 2). All SBEM signals were expressed relative to the signal of tumour sample no. 4 (quantification of SBEM mRNA levels SEM; Table 2).
###end p 23
###begin p 24
Correlation of SBEM gene and protein expression in the small panel of 10 breast cancers
###end p 24
###begin p 25
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SBEM</italic>
SBEM gene expression was primarily assessed by Northern blotting and secondarily by reverse transcriptase-polymerase chain reaction (RT-PCR) analysis, whereas protein expression was assessed by immunohistochemistry (IHC) and Western blot.
###end p 25
###begin p 26
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
###end p 26
###begin title 27
Northern blot analysis
###end title 27
###begin p 28
###xml 183 185 182 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28">28</xref>
###xml 238 242 237 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SBEM</italic>
###xml 242 244 241 243 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 296 298 295 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b29">29</xref>
Total RNA (3-15 mug) was separated by electrophoresis on a 1% agarose gel and transferred to nylon membranes (Schleicher & Schuell BioScience, Keene, NH, USA) as previously described.28 The blot was hybridized with a 291-bp random-primed SBEM32P-labelled probe, generated as previously described.29 Equal loading and integrity of RNA were monitored by ethidium bromide staining of the 28s and 18s subunits of rRNA.
###end p 28
###begin title 29
Western blot analysis
###end title 29
###begin p 30
###xml 149 151 149 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19">19</xref>
###xml 314 316 313 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b26">26</xref>
Immunoblotting analysis of SBEM was performed using an SBEM monoclonal antibody H39C51 (Dr T. Colpitts, Abbott Laboratories), at a dilution of 1:500.19 Equal amounts of total protein lysates (25 mug) were extracted and analysed by sodium dodecyl sulphate-polyacrylamide gel electrophoresis as previously described,26 in the absence or presence of a SBEM neutralizing peptide.
###end p 30
###begin title 31
Immunohistochemistry
###end title 31
###begin p 32
###xml 115 122 114 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">Table 1</xref>
###xml 241 248 240 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">Table 1</xref>
###xml 326 328 325 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b30">30</xref>
###xml 368 370 367 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b31">31</xref>
Serial sections (5 mum) of the TMAs were stained with the SBEM monoclonal antibody H218C31 at a dilution of 1:800 (Table 1). Commercially available antibodies were utilized for Ki67, CK5/6, epidermal growth factor receptor (EGFR) and HER-2 (Table 1), while psoriasin/S100A7 antibody has been previously validated by our group.30 IHC was performed as recently reported.31 Briefly, sections were dewaxed, rehydrated and then submitted to heat-induced antigen retrieval for 8 min in the presence of a citrate buffer (CC1; Ventana Medical Systems, Tucson, AZ, USA) using an automated tissue immunostainer (Discovery Staining Module; Ventana Medical Systems). The initial dilution quoted above was diluted further 1:3 with buffer dispensed onto the slide with the primary antibody. For each set of experiments, a strong SBEM+ and an SBEM- tumour sample, as previously assessed by RT-PCR, were included as controls. SBEM monoclonal antibody H218C31 was further validated at the IHC level, by pre-incubation for 4 h at 4degreesC with a 20-fold excess of a SBEM peptide (69-89aa, RKDIPVLPKWVGDLPNGRVC).
###end p 32
###begin p 33
Details of antibodies and experimental conditions used for immunohistochemistry in the present study
###end p 33
###begin p 34
Mild and standard cell conditioning, using CC1 antigen retrieval buffer (Ventana Medical Systems).
###end p 34
###begin p 35
Ventana Medical Systems using protease-1 enzyme for antigen retrieval.
###end p 35
###begin p 36
SBEM, small breast epithelial mucin; EGFR, epidermal growth factor receptor; CK, cytokeratin; ER, oestrogen receptor.
###end p 36
###begin title 37
Quantification and cut-off selection
###end title 37
###begin p 38
###xml 1534 1536 1534 1536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b32">32</xref>
###xml 1537 1539 1537 1539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b34">34</xref>
Immunopositivity for SBEM protein expression in the TMAs was assessed using semiquantitative scoring (H-scores). H-scores were derived from a semiquantitative assessment of both staining intensity (scale 0-3) and the percentage of positive cells (0-100%), which, when multiplied, generated a score ranging from 0 to 300. TMA immunohistochemistry was evaluated independently by three investigators (G.P.S., C.P., P.H.W.) and where discordance (i.e. different scores given by different investigators) was found (30 discordant cases, which were 10% of our entire cohort), cases were re-evaluated and a consensus reached. Primary categorical analysis was as follows: breast cancers were considered SBEM+ with an IHC score of >0. Only cytoplasmic reactivity was evaluated and scored. Also, since there is at present no relevant clinical cut-off point reported for SBEM in the literature, several cut-off points were tested for the IHC score, equivalent to an absence of staining, a 25th percentile and median IHC score values. Results reported in this study were based only on an IHC score of >0. Positivity for psoriasin/S100A7 (a marker that correlates with indicators of poor prognosis) and CK5/6 (one of the markers of basal phenotype) was set at >0, for Ki67 at >30 (corresponding to the median of the ER- TMA), whereas for EGFR and HER-2, only breast cancers that showed strong, intense membranous immunopositivity of IHC 3+ (>30% of invasive tumour cells) were considered positive, as reported, used and recommended by other groups.32-34
###end p 38
###begin title 39
Statistical analysis
###end title 39
###begin p 40
###xml 64 65 64 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
Correlations were assessed by Spearman's rank correlation test (r), whereas associations between SBEM and other clinicopathological variables were tested using contingency methods (Fisher's exact test). Kruskal-Wallis test and Dunn's method test (which compares all pairs of columns) were taken as correction for multiple analyses. Univariate survival analyses were performed using the log rank test to generate Kaplan-Meier curves. Overall survival (OS) was defined as the time from initial surgery to the date of death attributable to breast cancer only. Relapse-free survival (RFS) was defined as the time from initial surgery to the date of clinically documented local or distant disease recurrence or death attributed to breast cancer. Statistical analyses were carried out using GraphPad Prism 4.02 version (GraphPad, San Diego, CA, USA) and SPSS 12 for windows statistics software (SPSS Inc., Chicago, IL, USA).
###end p 40
###begin title 41
Results
###end title 41
###begin title 42
SBEM mRNA and protein expression in primary breast cancers
###end title 42
###begin p 43
As a first step in assessing SBEM protein expression, we examined whether an association existed between RNA and protein levels in a small panel of 10 randomly selected primary breast cancers. Serial sections obtained from biopsy specimens were evaluated for gene expression by both RT-PCR and Northern blot analysis, whereas protein expression was assessed by IHC and Western blot analysis.
###end p 43
###begin p 44
###xml 96 100 96 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SBEM</italic>
###xml 120 129 120 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig01">Figure 1A</xref>
###xml 245 254 245 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig01">Figure 1A</xref>
###xml 256 263 256 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl2">Table 2</xref>
###xml 422 426 410 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SBEM</italic>
###xml 589 598 577 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig01">Figure 1B</xref>
All breast cancers were positive by RT-PCR (10/10) and a single band of 291 bp corresponding to SBEM mRNA was detected (Figure 1A). Various levels of expression were observed (low to moderate in tumour samples 1, 3, 4 and 9; high in all others; Figure 1A, Table 2). Only tumours that showed the highest expression by RT-PCR were also positive by Northern blot analysis. Northern blot analysis showed a approximately700-bp SBEM transcript, which was identified in six out of 10 samples, with the highest level of expression observed in tumour sample no. 5 followed by tumour sample no. 10 (Figure 1B).
###end p 44
###begin p 45
###xml 129 130 129 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 221 222 221 222 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 401 402 401 402 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 663 667 661 665 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SBEM</italic>
###xml 667 669 665 667 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 776 777 774 775 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 55 60 <span type="species:ncbi:9606">human</span>
SBEM RNA and protein expression in a small panel of 10 human breast cancers. RNA and protein were extracted from breast cancers (n = 10) as described in Materials and Methods. Numbers (1-10) represent individual tumours. A, RT-PCR analysis. 'N' is a negative RT-PCR, i.e. reverse transcription performed minus MMLV enzyme, and 'B' is a PCR negative control. Lane M, PhiX174 RF DNA/Hae III DNA ladder. B, Northern blot analysis. Breast cancers were analysed as described in Materials and methods. Fifteen micrograms of total RNA from tumours 1-7, three from tumour no. 8, 10 mug from no. 9 and 6 mug from no. 10 were separated on agarose gels and hybridized using SBEM32P-labelled probes. Loading controls are provided with 18s and 28s RNA bands on the bottom panel M, ladder. C, Western blot analysis. Total proteins (25 mug) were analysed by sodium dodecyl sulphate-polyacrylamide gel electrophoresis using the SBEM H39C51 monoclonal antibody. M = ladder.
###end p 45
###begin p 46
###xml 125 129 125 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SBEM</italic>
###xml 207 216 207 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig01">Figure 1C</xref>
###xml 247 251 247 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SBEM</italic>
Western blot analysis revealed detectable levels of SBEM protein only in tumour sample no. 5 (which corresponded to the high SBEM mRNA expressor detected by Northern blot), whereas all others were negative (Figure 1C). In addition to the expected SBEM band, a 25-kDa band was sometimes apparent. However, only the approximately17-kDa band was related to SBEM protein, as repeatedly confirmed by peptide competition assay (data not shown).
###end p 46
###begin p 47
###xml 117 124 117 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl2">Table 2</xref>
###xml 126 134 126 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig02">Figure 2</xref>
###xml 212 223 212 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig03">Figure 3E,F</xref>
###xml 311 318 311 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl2">Table 2</xref>
###xml 320 328 320 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig02">Figure 2</xref>
###xml 652 656 652 656 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SBEM</italic>
###xml 696 697 696 697 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 707 708 707 708 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 729 730 729 730 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 800 807 800 807 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl2">Table 2</xref>
Results from immunohistochemical analysis revealed that seven of the 10 breast cancers were immunopositive for SBEM (Table 2; Figure 2). Incubation with a 20-fold excess of the peptide abolished the SBEM signal (Figure 3E,F). The highest protein levels were detected in tumour no. 5, followed by tumour no. 10 (Table 2; Figure 2). No immunoreactivity was noted in tumours 1, 4 or 6. Notably, in tumours 4, 7 and 10, immunopositivity was observed in the surrounding normal mammary gland (data not shown), whereas in tumour no. 3, some normal breast ducts were SBEM+ (data not shown). Overall, SBEM protein expression (determined by IHC) correlated with SBEM gene expression [determined by RT-PCR (r = 0.727, P = 0.017 two-tailed, n = 10) and also by Northern blot analysis (tumours 5, 10, 8, 7 and 2; Table 2)].
###end p 47
###begin p 48
###xml 87 88 87 88 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 191 192 191 192 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 245 246 245 246 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 309 310 309 310 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 365 366 365 366 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 529 530 529 530 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
SBEM expression, determined by immunohistochemistry in ER+ and ER- tissue microarrays. A, ER+ cancer stained with the SBEM monoclonal antibody (H218C31) showing no expression (H-score of 0). B, ER+ tumour showing low expression (H-score of 30). C, ER+ breast cancer showing medium expression (H-score of 60). D, ER+ tumour showing high expression (H-score of 225). E, ER- breast cancer (ER and PR levels of 2.3 and 8.9 fmol/mg protein, respectively) immunoreactive for the H218C31 SBEM-specific antibody showing high expression. F, Serial section of the ER- breast cancer, where the primary antibody was incubated with x20-fold excess SBEM peptide and abolished the specific stain.
###end p 48
###begin p 49
###xml 73 78 <span type="species:ncbi:9606">human</span>
###xml 169 176 <span type="species:ncbi:9606">Patient</span>
Immunohistochemical analysis of SBEM expression in the small panel of 10 human breast cancers. Immunohistochemistry was performed as described in Materials and Methods. Patient/sample identification is indicated on top left of each picture, and the corresponding H-score for IHC is presented on the bottom right corner. H-scores were derived from semiquantitative assessment of both staining intensity (scale 0-3) and the percentage of positive cells (0-100%) and, when multiplied, generate a score ranging from 0 to 300. Bar = 50 mum.
###end p 49
###begin title 50
###xml 94 95 94 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
SBEM protein expression and clinicopathological prognostic variables in breast cancer cohort (n = 300)
###end title 50
###begin p 51
###xml 133 140 133 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">Table 1</xref>
###xml 508 515 508 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl3">Table 3</xref>
###xml 621 622 621 622 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 790 791 790 791 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 804 805 802 803 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 873 880 871 878 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl3">Table 3</xref>
###xml 948 950 946 948 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b30">30</xref>
###xml 951 953 949 951 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b35">35</xref>
###xml 954 956 952 954 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b36">36</xref>
###xml 1042 1043 1040 1041 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1053 1054 1051 1052 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1126 1127 1120 1121 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1137 1138 1131 1132 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1361 1368 1355 1362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl3">Table 3</xref>
###xml 1467 1476 1461 1470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig04">Figure 4A</xref>
###xml 1683 1684 1677 1678 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1694 1695 1688 1689 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1755 1764 1749 1758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig04">Figure 4B</xref>
Serial TMA sections were stained using IHC with specific antibodies recognizing SBEM, Ki67, CK5/6, EGFR, HER-2 and psoriasin/S100A7 (Table 1). Cytoplasmic reactivity was observed and scored for SBEM and positivity was defined as an IHC score of >0. From our studies, data on SBEM protein expression in 300 breast cases were obtained, but for the analysis of some of the other markers the numbers of cases analysed are slightly lower due to missing tumour cores on the TMAs, or unavailable data for analysis (Table 3). In this combined cohort of ER+ and ER- invasive breast cancers, 18% of tumours were positive for SBEM (n = 53/300). Using categorical analysis (i.e. SBEM defined as positive or negative), SBEM was strongly positively associated with psoriasin/S100A7 [Fisher's exact test, P </= 0.0001, n = 280, odds ratio (OR) 6.77, 95% confidence interval (CI) 3.2, 14; Table 3], a marker that correlates with other indicators of poor prognosis,30,35,36 and negatively associated with Ki67, a marker of proliferation (Fisher's exact test, P = 0.009, n = 230, OR 0.356, 95% CI 0.16, 0.78), and ERalpha (Fisher's exact test, P = 0.049, n = 300, OR 0.536, 95% CI 0.29, 0.98). No other statistically significant associations between SBEM and established prognostic factors such as tumour size, axillary lymph node status and progesterone receptor were observed (Table 3). Interestingly, even though no association existed between overall survival and SBEM expression (Figure 4A), a trend toward significance was observed for those breast cancers that exhibited high levels of SBEM positivity and a shorter time to disease progression, compared with those that were SBEM- [low levels, P = 0.057, n = 300, hazard ratio (HR) 0.65, 95% CI of ratio 0.37, 1.04; Figure 4B]. This trend, along with the strong association observed with psoriasin expression, prompted us to examine further the relationship between SBEM protein expression and the ER status of the tumours.
###end p 51
###begin p 52
###xml 63 71 <span type="species:ncbi:9606">patients</span>
Distribution of SBEM+ and SBEM- cases within the cohort of 300 patients
###end p 52
###begin p 53
###xml 116 118 116 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n)</italic>
###xml 120 121 120 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
For each characteristic, clinical and pathological (see Materials and Methods), the total number of cases is given (n). P-values have been calculated following Fisher's exact test. Cut-offs were previously set (Materials and Methods). Statistical analysis was performed with GraphPad Prism 4.02 software (San Diego, CA, USA), and statistically significant values are in bold.
###end p 53
###begin p 54
EGFR, epidermal growth factor receptor; CK, cytokeratin; PR, progesterone receptor; LBA, ligand binding assay; ER, oestrogen receptor.
###end p 54
###begin p 55
###xml 143 146 143 146 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A,B</bold>
###xml 160 163 156 159 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C,D</bold>
###xml 187 190 179 182 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E,F</bold>
###xml 245 246 237 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 284 285 276 277 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 298 299 290 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 352 353 344 345 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 367 368 359 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 421 422 413 414 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 431 432 423 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 485 486 477 478 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 496 497 488 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 550 551 542 543 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 567 568 559 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 620 621 612 613 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
###xml 638 639 630 631 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
Kaplan-Meier graphs for overall survival and relapse free survival-time to progression for SBEM expression in the entire breast cancer cohort (A,B), ER alpha- (C,D) and ERalpha+ cancers (E,F). Symbols on the graph lines represent censored data, P-values are given for log rank tests. A (top left), n = 300; low SBEM events = 80, high SBEM events = 23; B (top right), n = 300; low SBEM events = 95, high SBEM events = 26; C (left), n = 149; low SBEM events = 57, high SBEM events = 16; D (right), n = 149; low SBEM events = 55, high SBEM events = 17; E (bottom left), n = 151; low SBEM events = 23, high SBEM events = 7; F (bottom right), n = 151; low SBEM events = 40, high SBEM events = 9.
###end p 55
###begin title 56
SBEM protein expression, clinicopathological prognostic variables and survival in ER- breast cancers
###end title 56
###begin p 57
###xml 68 69 68 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 212 213 212 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 222 223 222 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 234 235 234 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 330 331 330 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 341 342 341 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 353 354 353 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 450 451 450 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 461 462 461 462 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 473 474 473 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 614 615 614 615 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 628 629 628 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 665 672 665 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl4">Table 4</xref>
###xml 730 731 730 731 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 741 742 741 742 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 778 785 778 785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl4">Table 4</xref>
###xml 895 896 895 896 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 909 910 909 910 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 953 956 953 956 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P =</italic>
###xml 967 968 967 968 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1007 1014 1007 1014 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl4">Table 4</xref>
###xml 1111 1112 1111 1112 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1123 1124 1123 1124 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1299 1306 1299 1306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl4">Table 4</xref>
###xml 1416 1427 1416 1427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig04">Figure 4C,D</xref>
In the ER- breast cancers analysed, only 22% of tumours were SBEM+ (n = 33/149). There was a positive and statistically significant correlation between SBEM and psoriasin/S100A7 expression (Spearman coefficient, r = 0.44, P < 0.0001, n = 146, 95% CI 0.29, 0.56). A significant inverse correlation with Ki67 (Spearman coefficient, r = -0.39, P < 0.0001, n = 148, 95% CI -0.52, -0.23) and CK5/6, a basal epithelial phenotype marker, was also observed (r = -0.34, P < 0.0001, n = 130, 95% CI -0.48, -0.17). Univariate analysis showed that SBEM was significantly associated with psoriasin/S100A7 (Fisher's exact test, P = < 0.0001, n = 146, OR 14.48, 95% CI 3.3, 63.5; Table 4) and less significantly with HER-2 (Fisher's exact test, P = 0.046, n = 135, OR 2.39, 95% CI 1.04, 5.48; Table 4). In the same cohort, SBEM was negatively associated with Ki67 and CK5/6, respectively (Fisher's exact test, P = < 0.0001, n = 148, OR 0.232, 95% CI 0.098, 0.545; and P = < 0.0001, n = 130, OR 0.147, 95% CI 0.057, 0.381; Table 4), whereas lack of SBEM expression was associated with higher tumour grade (Fisher's exact test, P = 0.0015, n = 139). No other statistically significant associations between SBEM and established prognostic factors such as tumour size, axillary lymph node status and PR were observed (Table 4). Furthermore, no difference in disease outcome (OS and RFS) was found between low and high SBEM expression (Figure 4C,D).
###end p 57
###begin p 58
###xml 61 62 61 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
Distribution of SBEM+ and SBEM- cases within the ER- cohort (n = 149)
###end p 58
###begin p 59
###xml 115 116 115 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 119 120 119 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
For each clinical and pathological characteristic (see Materials and Methods), the total number of cases is given (n). P-values have been calculated following Fisher's exact test. Cut-offs were previously set (Materials and Methods). Statistical analysis was performed with GraphPad Prism 4.02 software (San Diego, CA, USA), and statistically significant values are in bold.
###end p 59
###begin p 60
EGFR, epidermal growth factor receptor; CK, cytokeratin; PR, progesterone receptor; LBA, ligand binding assay.
###end p 60
###begin title 61
SBEM protein expression, clinicopathological prognostic variables and survival in ER+ breast cancers
###end title 61
###begin p 62
###xml 43 44 43 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 85 96 85 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig03">Figure 3A&#8211;D</xref>
###xml 209 210 209 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 219 220 219 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 230 231 230 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 285 286 285 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 296 297 296 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 335 342 335 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl5">Table 5</xref>
###xml 462 469 462 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl5">Table 5</xref>
###xml 735 736 735 736 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 790 791 790 791 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 855 866 855 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig04">Figure 4E,F</xref>
###xml 630 638 <span type="species:ncbi:9606">patients</span>
In the ER+ breast cancers, 13% of tumours (n = 20/151) were immunopositive for SBEM (Figure 3A-D). SBEM was significantly correlated and associated with psoriasin/S100A7, respectively (Spearman's coefficient, r = 0.21, P = 0.015, n = 132, 95% CI 0.036, 0.373; and Fisher's exact test, P = 0.016, n = 134, OR 4.053, 95% CI 1.34, 12.21; Table 5). No other associations between SBEM and established prognostic factors were observed in this better prognosis cohort (Table 5). However, using the log rank test to generate Kaplan-Meier curves, an interesting trend toward significance was observed in disease outcome (OS and RFS), with patients with higher SBEM levels being associated with worse survival and a shorter time to progression (P = 0.063, HR 0.461, 95% CI of ratio 0.117, 1.060; and P = 0.072, HR 0.522, 95% CI of ratio 0.172, 1.078, respectively; Figure 4E,F).
###end p 62
###begin p 63
###xml 69 70 69 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
Distribution of SBEM+ and SBEM- cases within the ER-positive cohort (n = 151)
###end p 63
###begin p 64
###xml 111 112 111 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 115 116 115 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
For each clinical and pathological characteristic (Materials and Methods), the total number of cases is given (n). P-values have been calculated following Fisher's exact test. Cut-offs were previously set (Materials and Methods). Statistical analysis was performed using the GraphPad Prism software version 4.02 (San Diego, CA, USA), and statistically significant values are in bold.
###end p 64
###begin p 65
EGFR, epidermal growth factor receptor; CK, cytokeratin; PR, progesterone receptor; LBA, ligand binding assay.
###end p 65
###begin title 66
SBEM protein expression in normal breast tissue
###end title 66
###begin p 67
###xml 73 76 <span type="species:ncbi:9685">cat</span>
IHC was also performed on a TMA consisting of 68 normal tissues (Biomax; cat. No. BN08013). Moderate to strong immunoreactivity for SBEM was detected in nine normal tissues (three breast ducts, six fibro-fatty tissues) and SBEM expression was calculated at 13% (9/68 cases). Three malignant breast biopsy specimens, included as markers for orientation purposes in the TMA, showed no specific SBEM reactivity (0/3). A highly positive SBEM breast cancer sample and a SBEM- one, previously assessed by RT-PCR, were used as controls, for IHC analysis.
###end p 67
###begin title 68
Discussion
###end title 68
###begin p 69
###xml 1081 1082 1081 1082 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 114 119 <span type="species:ncbi:9606">human</span>
Most data on SBEM thus far have been accumulated from gene expression studies, whereas SBEM protein expression in human breast cancers has not been explored. As a first step in addressing SBEM protein expression in breast cancer, we examined the relationship between gene and protein expression. As expected, differences were observed when using techniques with known different levels of sensitivity. For example, when all samples were positive using RT-PCR, SBEM protein was detected in only one tumour by Western blot analysis. This underscores the critical importance of setting standards and references to be used in the assessment of expression of a specific biomarker for clinical management purposes. A significant correlation was found between results from protein assessment by IHC and RNA measurement by semiquantitative RT-PCR. This finding was surprising, as even though IHC is currently used to assess biomarker positivity (ER, for example), we were not expecting statistical significance when comparing with a semiquantitative assay performed on such a small cohort (n = 10). This suggests that a strong association exists between SBEM RNA and protein expression. It also suggests that an even better estimation of the expression of this gene might be performed with the more quantitative real-time PCR. If SBEM is to be used as a clinical biomarker, the possibility of accurately measuring its levels from a tiny amount of tissue (biopsy specimen) is another major advantage to be considered.
###end p 69
###begin p 70
###xml 531 533 527 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b30">30</xref>
###xml 534 536 530 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b35">35</xref>
###xml 537 539 533 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b36">36</xref>
###xml 1156 1157 1148 1149 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1200 1202 1192 1194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b37">37</xref>
###xml 1437 1439 1429 1431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">20</xref>
###xml 625 632 <span type="species:ncbi:9606">patient</span>
###xml 1036 1044 <span type="species:ncbi:9606">patients</span>
###xml 1689 1697 <span type="species:ncbi:9606">patients</span>
###xml 1893 1901 <span type="species:ncbi:9606">patients</span>
The findings presented here include the largest number of breast cancers to date to examine SBEM protein expression. In a combined cohort of 300 ER+ and ER- invasive breast cancers, it was found that 18% of cancers were positive for SBEM. SBEM was also found to be highly associated with psoriasin/S100A7, a member of the S100 family of genes. Psoriasin/S100A7 is known to correlate with indicators of poor prognosis, specifically in ERalpha- breast cancers, and may represent an independent prognostic factor for clinical outcome.30,35,36 To investigate SBEM protein expression further in separate subgroups, we divided the patient cohort according to ER status (as determined by both the ligand binding assay and IHC). In the ERalpha- TMA, which represents a more aggressive group of breast cancers, SBEM protein was detected in 22% of breast cancers. Univariate analysis showed that SBEM was strongly associated with psoriasin/S100A7 and less so with HER-2, the latter being well documented to confer poor prognosis in breast cancer patients. Interestingly, a significant association between HER-2 determined by IHC and increasing amounts of SBEM mRNA (P = 0.003) has also been reported by others.37 These results suggest that SBEM, like psoriasin/S100A7 and HER-2, may also be associated with poor prognosis, an observation which is consistent with our previous findings that SBEM mRNA expression was higher in node-positive tumours.20 Interestingly, in the ER-positive/node-negative cohort, SBEM expression was also significantly associated with psoriasin/S100A7, and perhaps identifies, within a breast cancer cohort generally considered to have a very good prognosis, a minority of patients more likely to experience recurrence of disease. This is emphasized by the fact that strong trends were observed toward both a lower survival rate and a higher recurrence of the disease in SBEM+ patients. SBEM protein, however, was more frequently expressed in ER- breast cancers, consistent with its positive association with psoriasin/S100A7 and HER-2. Furthermore, it is interesting that a SBEM correlation exists with Ki67, but not with tumour grade. However, correlation with proliferation index but not with grade could arise from lack of association or competing association with the other components of tumour grade (which was based on the Nottingham grading score, in which the grade reflects nuclear morphology and tubular differentiation, as well as proliferation rate). Further pathological analysis is required to explore this aspect.
###end p 70
###begin p 71
###xml 348 350 348 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b23">23</xref>
###xml 351 353 351 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b38">38</xref>
###xml 354 356 354 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b39">39</xref>
###xml 688 690 688 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">20</xref>
###xml 889 891 889 891 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b22">22</xref>
###xml 1073 1075 1073 1075 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b23">23</xref>
###xml 1086 1090 1086 1090 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SBEM</italic>
###xml 1266 1268 1266 1268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b37">37</xref>
###xml 1268 1272 1268 1272 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SBEM</italic>
###xml 1485 1487 1485 1487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b37">37</xref>
###xml 391 399 <span type="species:ncbi:9606">patients</span>
###xml 1064 1072 <span type="species:ncbi:9606">patients</span>
###xml 1231 1239 <span type="species:ncbi:9606">patients</span>
Because of the heterogeneous nature of breast cancers, it is unlikely that any single tumour marker would be sufficient for breast cancer diagnosis or detection of metastasis. Indeed, an increasing number of reports have suggested that the use of multiple markers could indeed improve the likelihood of detecting tumour cells across the population.23,38,39 Identification of a new subset of patients using SBEM protein detection would be likely to enhance the potency of such a multimarker set. In line with such a multimarker strategy to disease management, we have previously shown that both SBEM and mammaglobin gene expression correlate positively with axillary lymph node metastasis.20 SBEM has also been included in a list of markers (18 in total) currently used for the detection of disseminated tumour cells, and their significance and limitations have been reviewed and discussed.22 In addition, a marker set containing CK19, p1B, EGP2 and SBEM has been reported to facilitate the discrimination between negative and positive lymph nodes in breast cancer patients.23 Recently, SBEM (BS106) gene expression has also been investigated with real-time PCR in a series of breast cancers, lymph nodes from cancer and non-cancer patients and normal breast tissues.37SBEM was highly expressed in all but one breast cancers and in all normal breast tissues. The authors concluded that SBEM added to the potential utility of other markers in breast cancer, such as mammaglobin and CK19.37
###end p 71
###begin p 72
###xml 632 634 632 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b40">40</xref>
###xml 635 637 635 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b42">42</xref>
###xml 804 806 804 806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b43">43</xref>
###xml 807 809 807 809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b44">44</xref>
The TMAs used in this study were constructed with duplicate cores (0.6 mm) derived from each tumour sample. Our results have shown some heterogeneity in SBEM staining. Furthermore, it may be a matter of concern whether two cores are entirely representative of gene expression in a large tumour sample, as they could result in both over- and underscoring of protein expression in the TMA. However, although we cannot entirely exclude this possibility, previous studies by others have shown that with use of the standard breast cancer prognostic markers (ER, PR and HER-2), two cores are sufficient and have resulted in >95% accuracy.40-42 Similarly, two cores have also been reported to provide a high level of accuracy in the TMA analysis of other cancers, such as metastatic prostate and ovarian cancer.43,44
###end p 72
###begin p 73
###xml 312 320 <span type="species:ncbi:9606">patients</span>
Overall, SBEM expression was observed in 22% of ERalpha- and 13% of ERalpha+ breast cancers. No statistically significant association between SBEM expression and clinical outcome was observed. However, in ER+ breast cancers a definite trend toward significance between SBEM protein levels and disease outcome of patients was observed, suggesting that SBEM may be associated with worse survival and shorter time to progression in this specific subgroup. In ER- cancers, SBEM protein expression was highly associated with some markers of poor prognosis. We believe further analyses are needed, using real-time RT-PCR, to refine our assessment of SBEM expression in breast cancers. Altogether, these results suggest that SBEM may identify a unique subset of breast cancers and may have future implications for therapeutic management of the disease.
###end p 73
###begin title 74
Competing interests
###end title 74
###begin p 75
None to declare.
###end p 75
###begin p 76
G.P.S. is funded by a Postdoctoral Fellowship Award from the Manitoba Health Research Council (MHRC) and previously from the CancerCare Manitoba Foundation (CCMF). F.H. was a MHRC Fellow. Y.M. is a Manitoba Medical Service Foundation Career Awardee. This work was supported by the Canadian Institute of Health Research (CIHR no. MOP 62971). The authors thank Dr Tracy Colpitts and Abbott Laboratories for the SBEM monoclonal antibodies and the personnel at the MBTB for technical support. We acknowledge the strong support of the CCMF for our facilities at Manitoba Institute of Cell Biology.
###end p 76
###begin title 77
References
###end title 77
###begin article-title 78
IARC Screening Group, Breast Cancer Research Studies
###end article-title 78
###begin article-title 79
Global cancer statistics
###end article-title 79
###begin article-title 80
Natural history of node-positive breast cancer: the curability of small cancers with a limited number of positive nodes
###end article-title 80
###begin article-title 81
###xml 86 91 <span type="species:ncbi:9606">women</span>
A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma
###end article-title 81
###begin article-title 82
Hormone receptors: their role in predicting prognosis and response to endocrine therapy
###end article-title 82
###begin article-title 83
Steroid hormone receptors in breast cancer management
###end article-title 83
###begin article-title 84
Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases
###end article-title 84
###begin article-title 85
The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy
###end article-title 85
###begin article-title 86
###xml 32 37 <span type="species:ncbi:9606">human</span>
Prolactin-inducible proteins in human breast cancer cells
###end article-title 86
###begin article-title 87
Biochemistry and immunohistochemistry of fluid proteins
###end article-title 87
###begin article-title 88
###xml 91 96 <span type="species:ncbi:9606">human</span>
Mammaglobin, a mammary-specific member of the uteroglobin gene family, is overexpressed in human breast cancer
###end article-title 88
###begin article-title 89
Circulating tumour markers in breast cancer: accepted utilities and novel prospects
###end article-title 89
###begin article-title 90
Tumour marker measurements in the diagnosis and monitoring of breast cancer
###end article-title 90
###begin article-title 91
Prognostic molecular markers in early breast cancer
###end article-title 91
###begin article-title 92
The clinical significance of disseminated tumour cells in breast cancer
###end article-title 92
###begin article-title 93
Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma
###end article-title 93
###begin article-title 94
High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses
###end article-title 94
###begin article-title 95
Microarrays in breast cancer research and clinical practice - the future lies ahead
###end article-title 95
###begin article-title 96
Identification and immunohistochemical characterization of a mucin-like glycoprotein expressed in early stage breast carcinoma
###end article-title 96
###begin article-title 97
###xml 119 124 <span type="species:ncbi:9606">human</span>
Identification of a novel breast- and salivary gland-specific, mucin-like gene strongly expressed in normal and tumour human mammary epithelium
###end article-title 97
###begin article-title 98
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human small breast epithelial mucin: the promise of a new breast tumour biomarker
###end article-title 98
###begin article-title 99
Significance, detection and markers of disseminated breast cancer cells
###end article-title 99
###begin article-title 100
###xml 65 73 <span type="species:ncbi:9606">patients</span>
Detection of metastases in sentinel lymph nodes of breast cancer patients by multiple mRNA markers
###end article-title 100
###begin article-title 101
The NCIC-Manitoba Breast Tumour Bank: a resource for applied cancer research
###end article-title 101
###begin article-title 102
REporting recommendations for tumour MARKer prognostic studies (REMARK)
###end article-title 102
###begin article-title 103
Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in node-negative invasive breast cancer
###end article-title 103
###begin article-title 104
Protein measurement with the Folin phenol reagent
###end article-title 104
###begin article-title 105
Role of specific CCAAT/enhancer-binding protein isoforms in intestinal epithelial cells
###end article-title 105
###begin article-title 106
Mammaglobin, a potential marker of breast cancer nodal metastasis
###end article-title 106
###begin article-title 107
Psoriasin (S100A7) expression is associated with poor outcome in estrogen receptor-negative invasive breast cancer
###end article-title 107
###begin article-title 108
###xml 75 80 <span type="species:ncbi:9606">human</span>
Expression of oestrogen receptor-beta in oestrogen receptor-alpha negative human breast tumours
###end article-title 108
###begin article-title 109
Age interacts with the expression of steroid and HER-2 receptors in operable invasive breast cancer
###end article-title 109
###begin article-title 110
Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study
###end article-title 110
###begin article-title 111
###xml 101 106 <span type="species:ncbi:9606">Human</span>
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer
###end article-title 111
###begin article-title 112
Psoriasin (S100A7) expression and invasive breast cancer
###end article-title 112
###begin article-title 113
A putative role for psoriasin in breast tumour progression
###end article-title 113
###begin article-title 114
Evaluation of expression based markers for the detection of breast cancer cells
###end article-title 114
###begin article-title 115
Biomarkers in molecular medicine: cancer detection and diagnosis
###end article-title 115
###begin article-title 116
Protein expression profiling identifies subclasses of breast cancer and predicts prognosis
###end article-title 116
###begin article-title 117
Multiple tissue core arrays in histopathology research: a validation study
###end article-title 117
###begin article-title 118
Validation of tissue microarray technology in breast carcinoma
###end article-title 118
###begin article-title 119
Amplification of tissue by construction of tissue microarrays. Review
###end article-title 119
###begin article-title 120
Neuroendocrine expression in metastatic prostate cancer: evaluation of high throughput tissue microarrays to detect heterogenous protein expression
###end article-title 120
###begin article-title 121
Validation of tissue microarray technology in ovarian carcinoma
###end article-title 121
###begin title 122
Abbreviations:
###end title 122
###begin p 123
confidence interval
###end p 123
###begin p 124
cytokeratin
###end p 124
###begin p 125
epidermal growth factor receptor
###end p 125
###begin p 126
epithelial glycoprotein
###end p 126
###begin p 127
oestrogen receptor
###end p 127
###begin p 128
glyceraldehyde-3-phosphate dehydrogenase
###end p 128
###begin p 129
hazard ratio
###end p 129
###begin p 130
immunohistochemistry
###end p 130
###begin p 131
ligand binding assay
###end p 131
###begin p 132
Manitoba Breast Tumour Bank
###end p 132
###begin p 133
###xml 8 14 <span type="species:ncbi:10090">murine</span>
Moloney murine leukaemia virus
###end p 133
###begin p 134
odds ratio
###end p 134
###begin p 135
overall survival
###end p 135
###begin p 136
progesterone receptor
###end p 136
###begin p 137
relapse-free survival; RT-PCR, reverse transcriptase-polymerase chain reaction
###end p 137
###begin p 138
small breast epithelial mucin
###end p 138
###begin p 139
tissue microarray
###end p 139

